When you write a prescription, the pharmacy benefit determines whether your patient walks out with the medication that day, pays $10 or $400, or abandons therapy at the counter. For providers, understanding how pharmacy benefit plans, formularies, and PBM-driven cost structures actually work is the difference between a prescribed therapy and a started one. 

With new federal PBM reforms and benefit verification (BV) data more accessible than ever, the rules of the game are changing.

How the Pharmacy Benefit Works

A pharmacy benefit is the portion of a health plan covering prescription drugs, separate from the medical benefit, and it's typically managed not by the insurer but by a pharmacy benefit manager (PBM), a third party that acts as an intermediary between drug manufacturers and the plans offering coverage.

When a patient asks "Why is my medication so expensive?", the answer usually lies in the structure of their pharmacy benefit: the drug's formulary tier, whether cost-sharing is a copay or coinsurance, where they're in their deductible, and which pharmacies are in-network. 

PBMs make four decisions that drive nearly every patient-cost outcome you see in the clinic:

• Formulary design: Which drugs are covered, on what tier, and under what restrictions.
  
  

• Rebate negotiation: What manufacturer payments come back in exchange for preferred placement.
  
  

• Pharmacy network management: Which pharmacies a patient can use, and at what reimbursement rate.
  
  

• Utilization management: Prior authorization, step therapy, and quantity limits.

For the prescriber, the practical problem is that none of it is visible at the moment of prescribing.

How Formulary Tiers and Patient Cost Actually Work

The formulary is the PBM's drug coverage list, and tier placement is the single biggest predictor of what your patient will pay. According to the Kaiser Family Foundation 2025 Employer Health Benefits review, 84% of covered workers are enrolled in plans with three or more tiers of prescription drug cost sharing, and 60% are in plans with four or more tiers.

The Standard Five-Tier Formulary Structure

USC Schaeffer Center analysis found that nearly all Medicare Part D plans (97% of MA-PDs and 99% of PDPs) use a five-tier formulary framework, and the same structure dominates commercial design:

Exact dollar amounts vary widely by plan. For order-of-magnitude context, KFF's Employer Health Benefits Survey found that among workers in plans with three or more tiers, average copays rose from $11 at the first tier to $37 at the second, $67 at the third, and $116 at the fourth. Specialty-tier coinsurance averaged 27%.

The dollar gap between cost-sharing structures matters more than the tier numbers suggest. USC Schaeffer Center research found that monthly out-of-pocket spending for Eliquis, Medicare Part D's top-grossing drug, averaged $39-$46 when plans used copayments versus $92-$121 when plans used coinsurance.

Copay vs. Coinsurance: Why It Matters at the Counter

A copay is a fixed dollar amount; coinsurance is a percentage of the drug's list price. The distinction is critical because list prices don't reflect manufacturer rebates. When a plan applies coinsurance, the patient pays a percentage of the list price even though the plan and PBM may have negotiated rebates that lower the plan's actual net cost. For top-grossing branded drugs like Eliquis, those rebates averaged 45-50% off list price in 2023. The patient at the counter doesn't see the rebated price, just the coinsurance applied to the list price.

The trend is moving in the wrong direction for patients. Between 2020 and 2024, stand-alone Medicare Prescription Drug Plans systematically switched from copayments to coinsurance for preferred brands, shifting a greater cost-sharing burden directly to beneficiaries.

The Deductible Phase Trap

Even when a plan has reasonable copays, deductibles can blindside patients. In 2026, no Medicare drug plan can have a deductible exceeding $615, and many commercial high-deductible plans run thousands higher. During the deductible phase, patients pay the negotiated price of the drug, not the copay, which means a January prescription can cost ten times what the same prescription costs in June.

Bottom line: The formulary tier tells you part of the story. The patient's deductible status, coinsurance vs. copay structure, and any specialty-tier coinsurance maximum make up the rest. You can't know any of this from the patient's insurance card.

Why Drug Cost Transparency Has Been Broken

The fundamental problem with the pharmacy benefit system is informational asymmetry. As KFF documents, financial contracts between PBMs and drug manufacturers, including drug pricing information and rebate arrangements, are generally not made public. Plan sponsors often don't have insight into how much PBMs are actually paying for drugs on their formularies, and PBMs typically consider this information proprietary.

This opacity creates predictable consequences:

• Patients in the deductible phase pay the full list price, while employers receive downstream rebates.
  
  

• Plan sponsors can't audit what their PBM is actually charging vs. paying pharmacies.
  
  

• Independent pharmacies face spread pricing, being reimbursed less than what the PBM bills the plan.
  
  

• Providers have no way to predict what a given prescription will cost a given patient on a given day.

As the FTC’s complaint against the three largest PBMs put it, patients with deductibles and coinsurance often must pay the unrebated higher list price and do not benefit from rebates at the point of sale. 

The 2026 PBM Reform Landscape

On February 3, 2026, Congress enacted the Consolidated Appropriations Act of 2026, incorporating reform language from H.R. 7148. The legislation passed the Senate 71-29 on January 30 before being signed into law.

What's Changing And When

The reform unfolds across several years:

• Effective now (transparency): The Department of Labor's proposed rule from January 29, 2026 requires commercial PBMs to report rebates, spread pricing, and pharmacy recoupments to ERISA plan fiduciaries.
  
  

• Beginning 2028 (Medicare delinking): Part D plans must compensate PBMs only through flat, "bona fide service fees" reflecting fair market value, no more rebate-linked compensation structures.
  
  

• Beginning 2029 (any willing pharmacy): Prescription drug plans must allow any pharmacy meeting standard contract terms to participate in their networks, with HHS-defined "reasonable and relevant" terms.
  
  

• 2029 (commercial reforms): CAA requirements for commercial group health plans take effect for plan years beginning on or after January 1, 2029.

The Congressional Budget Office estimates the reforms will reduce the federal deficit by $2.1 billion over 10 years.

What This Actually Means at the Point of Prescribing

For providers, the practical impact will play out in three ways. 

First, formulary placement will become less rebate-driven over time, which should make tier placement track more closely with cost and clinical factors that prescribers can reason about.

Second, plan sponsors with audit authority will pressure PBMs to justify formulary decisions more rigorously, which may surface pricing data that's currently invisible. 

Third, and most relevant to daily workflow, the push for transparency creates a regulatory tailwind for real-time benefit verification tools that surface true patient cost at the point of prescribing.

As American Pharmacists Association EVP and CEO Michael D. Hogue, PharmD, told Pharmacy Times, the reforms signal progress toward a modernized payment system that recognizes the essential role of pharmacists in dispensing.

How Benefit Verification Surfaces Real Patient Cost

Benefit verification is the process of confirming, before a prescription is filled, what a specific patient will actually pay for a specific drug under their specific plan. Done well, BV pulls four data points: coverage status, formulary tier, prior authorization requirement, and out-of-pocket estimate.

When done poorly or manually, BV is the reason your medical assistant is on hold for 45 minutes while three other patients wait.

Real-Time Benefit Check (RTBC) and Beyond

Modern BV combines several data sources. Real-time benefit check (RTBC) tools, sometimes called real-time benefit tools (RTBTs) in CMS regulation, are built on the National Council for Prescription Drug Programs (NCPDP) Real-Time Prescription Benefit standard. They exchange information directly between PBMs and EHRs to return formulary, PA status, and estimated patient cost in seconds. When RTBC data is incomplete, which is common for newer drugs, less common plans, or specialty medications, automated phone calls to payers, faxed inquiries, or human follow-up fill the gaps.

The result is a coverage picture that lets you have an informed conversation with the patient before they leave: "This is covered at $35/month at your preferred pharmacy," or "This requires prior authorization that typically takes 48 hours," or "Your insurer prefers a different drug in this class; here's what that one costs."

The Cost of Not Doing This Well

The status quo is expensive. According to the American Medical Association's 2024 Prior Authorization Physician Survey, practices complete an average of 39 prior authorization requests per physician per week, with physicians and staff spending 13 hours weekly on the process. 40% of physicians employ staff who work exclusively on prior authorizations.

The downstream patient impact is worse. The AMA reports that 79% of physicians said prior authorization led to patients paying out of their own pocket for a medication, and 82% reported that PA can sometimes lead to patients abandoning their recommended course of treatment. 29% of physicians reported that prior authorization caused a serious adverse event for a patient in their care.

Pro tip: When evaluating BV and PA automation tools, ask vendors for their performance on three metrics: time to coverage answer, prior authorization approval rate, and prescription-to-approval cycle time. Generic "automation" claims without these metrics aren't worth your team's evaluation hours.

Frequently Asked Questions

What is a pharmacy benefit manager (PBM)?

A pharmacy benefit manager is a third-party company that administers prescription drug benefits on behalf of health insurers, employer plans, Medicare Part D plans, and Medicaid programs. PBMs negotiate with drug manufacturers, design formularies, manage pharmacy networks, and process pharmacy claims. The three largest PBMs, CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth), manage 79% of U.S. prescription drug claims on behalf of 270 million people, according to FTC data cited by the Kaiser Family Foundation.

How do formulary tiers affect what my patient pays?

Tier placement determines whether the patient pays a small copay (Tier 1, often $0-$10), a moderate copay (Tier 2-3, typically $10-$80), or coinsurance based on a percentage of list price (Tier 4-5, often 25-50%). Moving a drug from Tier 3 to Tier 4 can multiply the patient's monthly cost several times over, even when the drug itself hasn't changed.

What did the 2026 PBM reform law actually change? 

The Consolidated Appropriations Act of 2026 requires semiannual PBM transparency reporting to plan sponsors, delinks PBM compensation from Medicare Part D drug prices starting in 2028 (replacing rebate-based compensation with flat service fees), and creates "any willing pharmacy" network access standards beginning January 1, 2029. Most commercial-plan provisions also take effect for plan years beginning on or after January 1, 2029.

How long does prior authorization take, and can it be faster? 

Manual PA processes typically take 3-10 business days from submission to determination, with practices spending 13 hours per week per physician on the workflow. Automated platforms have demonstrated cycle-time reductions of more than 80%; Develop Health customers report moving from approximately 1.5 weeks to roughly 20 hours from prescription to approval, with an 83% reduction in PA handling time.

What's the best way for a practice to handle benefit verification at scale? 

The highest-leverage approach is embedding real-time benefit verification into the EHR prescribing workflow itself, so coverage status, PA requirement, and patient out-of-pocket cost surface before the patient leaves the visit. This eliminates the post-visit phone-tag cycle that drives most prescription abandonment, lets prescribers have informed cost conversations in real time, and frees clinical staff from administrative work that doesn't require their training.